INTRODUCTION
Chronic Lymphocytic Leukemia (CLL), the most common leukemia in the Western world, is characterized by the accumulation of monoclonal CD5+ mature B cells in the peripheral blood (PB), lymph nodes (LN) and bone marrow (BM). The majority of cases are diagnosed in asymptomatic patients with an incidental finding of lymphocytosis or lymphadenopathy. The standard of care for CLL is watchful waiting of asymptomatic patients and chemoimmunotherapy for patients with active disease (1) . This clinical approach to the CLL patient is guided by the absence of a curative chemotherapy regimen, the results of clinical trials that have shown no benefit for early chemotherapy in asymptomatic patients, and the relatively long natural history of the disease with a median survival of 11 years (2) . CLL is divided into two main subgroups based on the presence or absence of acquired somatic mutations in the immunoglobulin heavy-chain variable region (IGHV) expressed by the leukemic B cells. Patients with mutated IGHV have a more indolent disease and longer overall survival than patients whose tumors express an unmutated IGHV gene. High expression of ZAP70 and CD38 are additional markers indicating more rapid disease progression (3) . Cytogenetic alterations are also strong predictors of outcome. In particular, deletion of TP53 locus on 17p and deletion of the ATM locus on 11q are associated with more rapidly progressive disease and inferior response to chemotherapy. Increasingly, risk stratified treatment approaches are pursued for patients with these adverse prognostic markers (4) . CLL has historically been considered an accumulative disease of quiescent cells arrested in the G 0 /G 1 phase of the cell cycle and endowed with resistance to apoptosis. This notion has been based primarily on the study of leukemic cells from the peripheral blood. However, more recently it has been recognized that a proliferating subpopulation localized in lymphoid organs contributes to disease progression (5) (6) (7) . Interactions with the tissue microenvironment are crucial for CLL cell proliferation and survival (6, 8) . We recently demonstrated activation of the B-cell receptor (BCR) and nuclear factor-κB (NFκB) pathways in CLL cells isolated from the lymph node microenvironment. BCR signaling was stronger in the clinically more aggressive CLL subtype expressing unmutated IGHV genes and tumor proliferation in the lymph node correlated with clinical disease progression (7) . Thus, targeting the tumor microenvironment interactions and BCR signaling in particular has become a priority in CLL. Inhibitors of SYK (9), BTK (10) , and PI3K (11, 12) have shown promising preclinical and clinical activity in CLL. The PI3K/AKT pathway in particular is a key signaling node for several pathways implicated in CLL pathogenesis and interactions with the microenvironment including the BCR (13, 14) , CXCR4 (15) , CD40 (16) , CD44 (17) , and IL4 (13) . Moreover it has been shown that the PI3K pathway is Author Manuscript Published OnlineFirst on February 20, 2012 ; DOI: 10.1158/1078-0432.CCR- active in freshly isolated CLL cells (18) . PI3K activates AKT, a serine-threonine kinase critically involved in cell growth and survival ON 01910.Na, a styryl benzylsulfone is a non-ATP competitive multi-kinase inhibitor with marked anti-mitotic and anti-cancer activity. A phase I study in patients with solid tumors demonstrated good tolerability of the drug with an objective durable response in a patient with ovarian cancer (19) . ON 01910.Na is currently being tested in a randomized phase III trial in patients with refractory myelodysplastic syndrome (MDS) (registered as NCT01241500). Initially it was thought that the anti-mitotic activity was due to inhibition of polo-like kinase 1 (20) .
Subsequent studies did not support a direct effect on polo-like kinases (21) and a recent study correlated hyperphosphorylation of Ran GTPase-activating protein 1 with ON 01910.Na induced cell cycle arrest (22) . However, whether ON 01910.Na directly or indirectly contributes to mitotic arrest remains elusive. Focusing on mantle cell lymphoma (MCL), Prasad and colleagues showed direct inhibition of PI3K, preferentially of the p110α, p110β isoforms, resulting in decreased phosphorylation of AKT, inhibition of cyclin D1 translation, and induction of apoptosis in MCL cell lines (23). These results prompted us to explore the potential activity of ON 01910 against CLL cells. Here, we demonstrate that ON 01910.Na induces apoptosis in CLL cells irrespective of markers predicting resistance to classic chemotherapy while sparing normal lymphocytes. Using gene expression profiling we discovered that ON 01910.Na cytotoxicity is mediated by two main mechanisms: inhibition of the PI3K/AKT pathway and induction of an oxidative stress response. Moreover, ON 01910.Na remained active against CLL cells cocultured with stroma cells and reduced SDF-1-induced migration. These studies provide a rationale for the development of ON 01910.Na as a therapeutic agent in CLL.
MATERIALS AND METHODS

Patients and clinical samples
Blood samples from 34 CLL patients (table 1) were obtained with written informed consent.
Peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation using Lymphocyte Separation Medium (MP Biomedicals, Solon, OH) and used fresh or cryopreserved in liquid nitrogen in 10 % dimethyl sulfoxide, 90 % FCS. Analysis of IGHV gene status was performed as described (24). CLL samples were cultured in RPMI 1640 (Gibco-Invitrogen, Long Island, NY) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 2 mM Lglutamine, and penicillin/streptomycin (subsequently referred to as R10).
Research. 
Stromal cell coculture
The follicular dendritic cell line (FDC) HK kindly provided by Dr. Yong Sung Choi (25) , was cultured in IMDM (Gibco-Invitrogen, Long Island, NY) supplemented with 20% fetal bovine serum (HyClone), 2 mM L-glutamine, and penicillin/streptomycin. HK cells were seeded in 12-well plates on day 0. The next day IMDM was removed and CLL cells (2 x10 6 cells/ml in R10)
were added onto confluent stroma layers and cultured for the times indicated in the presence or absence of ON 01910.Na. CLL cells were recovered by gentle agitation, and the percentage of apoptotic cells was determined by flow cytometry after staining with CD19-FITC and AnnexinV-PE.
BCR stimulation by IgM crosslinking
CLL cells were reacted at 4°C for 30 minutes with 25μg/ml Goat F(ab')2 anti-human IgM-biotin (Southern Biotech) followed by the addition of 10μg/ml streptavidin (Jackson ImmunoResearch Laboratories) for 20 min. Cells were transferred to 37ºC for 30min and stimulation was stopped with cold PBS. Where indicated cells were pre-incubated with ON 01910.Na for 1 hour.
Migration assays
SDF-1α/CXCL12-induced migration was evaluated in 24 well chemotaxis chambers containing polycarbonate inserts of 5 µM pore size (Corning, Life Science). 100 µl cell suspensions at Gene expression profiling and gene set enrichment analysis (GSEA) 2.5µg total RNA was subjected to gene expression profiling on Human Genome U133 plus 2.0 chips (Affymetrix, Palo Alto, CA). Processing, data extraction and normalization was done as described (27) . Significant gene signatures were identified using GSEA v2.0 (Broad Institute at MIT, Cambridge, MA, http://www.broadinstitute.org/gsea/) using the C3 (motif gene sets) from the Molecular Signature Database v2.5, and experimentally derived custom gene sets (28) . An increasing profile analysis with 1000 permutations of gene sets and a weighted metric was used. Bonferoni correction for multiple testing was applied and only gene sets with a False Discovery Rate (FDR) ≤0.2 and a normalized enrichment score (NES) of >1.4 or <-1.4 were considered significant. The leading edge genes, i.e. the subset of genes that contributed most significantly to the identification of a gene set, were displayed using Cluster (v2.11) and TreeView (v1.6) softwares (Eisen Laboratory, Stanford University, USA).
Protein isolation and western blot
CLL cells were lysed in 1% Triton buffer containing PhosphoSTOP and the protease inhibitors 
Statistical analysis
Unpaired and paired T-tests were used to assess differences between two groups. P <0.05 was considered significant. 
RESULTS
ON 01910.Na activates the mitochondrial cell death pathway and is selectively toxic against CLL cells independent of IGHV mutational status and cytogenetic profile
To assess the cytotoxic effect of ON 01910.Na against CLL cells, we treated PBMC from CLL patients and healthy donors ex vivo with increasing concentrations of drug. We measured drug induced apoptosis in B and T cell populations separately using AnnexinV staining in combination with antibodies against the lineage specific markers CD19 and CD3. ON 01910.Na induced time-and dose-dependent cytotoxicity against B cells from CLL patients (Fig. 1A) . In contrast, there was no cytotoxic effect on T cells from CLL patients or B and T cells from healthy donors at 24 hours. At 48 hours normal B cells showed somewhat reduced viability albeit only at concentrations higher than those required to kill CLL cells. T cells from both normal donors and CLL patients remained largely unaffected even at concentrations of more than 8-fold the LD50 of CLL cells. Thus, ON 01910.Na is selectively toxic against CLL B cells.
We next determined the activity of ON 01910.Na against a panel of CLL samples from 34 patients stratified for disease markers that are associated with more aggressive disease and inferior survival (Table 1) . We determined the percentage of CD19 positive cells staining for Annexin V and calculated the LD50 for each sample at 48 hours. As shown in figure 1B , most of the patients had LD50 values between 1-2 µM, a concentration that is achieved in vivo (19) . CLL cells expressing mutated or unmutated IGHV genes were equally sensitive to ON 01910.Na and most cases with 17p or 11q deletions had LD50 values comparable to samples without these adverse cytogenetic findings (Table 1, Fig. 1B ).
To investigate whether ON 01910.Na activates the mitochondrial apoptotic pathway, CLL cells were treated with 2 µM ON 01910.Na for 24 hours. We used the mitotracker cell viability assay that measures mitochondrial depolarization to quantify drug induced apoptosis (Fig. 1C) . In parallel, we assessed activation of the proapoptotic proteins BAK and BAX using confirmation specific antibodies. Oligomerization of BAX and BAK enables the formation of the mitochondrial pore leading to mitochondrial depolarization, followed by the release of apoptogenic factors, and finally activation of effector caspases (29) . Both mitotracker staining and conformational changes in BAX and BAK indicate that ON 1910.Na activated the mitochondrial apoptotic pathway. Table S1 , Figure 2A) To validate the inhibition of PI3K/AKT pathway at protein level, we treated cells from CLL patients with 2 µM ON 01910.Na for 6 hours and assessed the phosphorylation status of AKT by western blot. pAKT was significantly reduced in most of the drug treated samples (Fig 2B   and 2C) . Furthermore, expression of the antiapoptotic protein MCL-1, which is in part regulated through increased translation downstream of PI3K/AKT signaling, also decreased in cells treated with ON 01910.Na ( Fig. 2B and C) . While about half of the samples showed >50% downregulation of pAKT in response to ON 01910.Na another half showed only minimal changes. This could be due to heterogeneity in cellular response to drug treatment or due to a relatively low baseline pAKT level in circulating CLL cells that makes it difficult to detect any further decrease. CLL cells in the peripheral blood are resting cells and, as we have recently shown, activation through signaling pathways, in particular the BCR occurs primarily in the lymph node microenvironment (7). Thus, having seen that treatment with ON 01910.Na down regulates BCR target genes, we next tested whether ON 01910.Na is able to block BCR activation in vitro. Indeed, ON 01910.Na was able to inhibit phosphorylation of AKT in response to BCR engagement by IgM crosslinking (Fig. 2D) .
Research. Although inhibition of the PI3K/AKT pathway may contribute to ON 01910.Na cytotoxic activity, this is unlikely to be the sole mechanism because cytotoxicity did not correlate well with the extent of PI3K/AKT blockade and the degree of apoptosis observed with ON 01910.Na was higher than what has been reported for other PI3K inhibitors (11, 15) . Further indicating a second mechanism of cytotoxic activity, GSEA identified a significant upregulation of genes controlled by the AP-1 transcription factor (Supplementary Table S1 , Fig. 3A) . AP-1 protein dimmers most commonly composed of JUN, FOS, or members of the ATF family, upon activation by JNK kinase, act as transcriptional transducers of stress pathways. The JNK/AP-1 pathway is an integral part of the cellular response to reactive oxygen species (ROS) (31) . In keeping with the gene expression data, we detected a dose-and time-dependent increase in ROS in response to ON 01910.Na that paralleled mitochondrial depolarization ( Fig. 3B and C) .
Thus, ON 01910.Na induces an oxidative stress response that activates the JNK pathway leading to the induction of AP-1 target genes.
To further determine the role of ROS in ON 01910.Na induced apoptosis we conducted cytotoxicity assays in presence of the antioxidant N-acetylcysteine (NAC). NAC reduced ROS generation by ON 01910.Na > 50% (p=0.002) and protected cells from the cytotoxic effect of the drug; while ON1910.Na on average killed more than 70% of cells at 48 hours, NAC potently antagonized the cytotoxic effect and all samples showed >50% viability (P=0.004, Fig. 3D ).
Next, we assessed the role of the JNK pathway in drug induced apoptosis by Western blotting and shRNA knockdown experiments. ON 01910.Na induced phosphorylation of JNK within 6 hours with concomitant upregulation of ATF3 and the nuclear accumulation of c-JUN (Fig. 4A and B ). In keeping with the known link between ROS and JNK activation (31), the ROS scavenger NAC reduced ON1910.Na induced phosphorylation of JNK (Fig. 4C) . We also found upregulation of the proapoptotic BH3-only protein NOXA in response to ON 01910.Na consistent with reports of a role for NOXA in the oxidative stress response (32, 33) . Finally, we used shRNAs to knock down NOXA and ATF3 in Jeko-1 cells ( Figure 4D cytotoxic effect of ON 01910.Na, further supporting the important contribution of the oxidative stress response and the JNK pathway to ON 01910.Na' mechanism of action.
ON 01910.Na overcomes stroma mediated pro-survival effects on CLL cells
It is well documented that the host microenvironment contributes to CLL cell proliferation, survival, and drug resistance (7, 8) . Thus, a critical need in CLL is the development of therapeutic approaches that remain highly active against tumor cells in the microenvironment.
Given the prominent role of the lymph node microenvironment for CLL cells, we assessed the efficacy of ON 01910.Na in an in-vitro model mimicking the lymph node environment by culturing CLL cells on the follicular dendritic cell line (FDC) HK (25) . As expected HK cells significantly increased the viability of co-cultured CLL cells compared to media alone ( NOXA in all CLL samples tested. It is notable that this stress response differs in some aspects from the NRF2 dominated response we described in MCL cells treated with the proteasome inhibitor bortezomib (33) . NRF2, a key regulator of the protective antioxidant response, is in part regulated through PI3K. The combination of a PI3K inhibitor with a ROS inducing agent has been shown to inhibit the translocation of NRF2 to the nucleus and block upregulation of NRF2 target genes (37, 38) . In keeping with this, ON 1910.Na treated cells mounted no significant NRF2 response (FDR>0.2, data not shown).
Pharmacologic induction of ROS is increasingly recognized as a therapeutic principle to selectively kill transformed cells (39, 40) . Cancer cells are particularly sensitive to disruption of redox homeostasis; a potential vulnerability thought to be due to increased ROS levels originating from oncogene activation (39) . One of the first agents shown to have selective antitumor activity through upregulation of ROS is beta-phenylethyl isothiocyanate (PEITC) (41).
This compound was subsequently shown to be effective against fludarabine-resistant CLL cells (42) . Similarly, apoptosis induced in CLL cells by adaphostin, a tyrosine kinase inhibitor of the tyrphostin class (43) , has been shown to depend on the induction of ROS. In vitro, these agents
Research.
on July 14, 2017. © 2012 American Association for Cancer clincancerres.aacrjournals.org Downloaded from remain active against chemotherapy-resistant CLL cells with dysfunctional TP53; an effect that seems to be primarily due to the induction of NOXA in response to ROS (32) . Despite their encouraging in-vitro activity, these agents have no established clinical benefit in CLL; adaphostin has not entered clinical testing, and a phase I study of PEITC is only about to begin (NCT00968461). In contrast, ON 01910.Na has recently entered a pivotal phase III clinical trials in MDS and is in phase I/II studies for other indications. Interestingly, ON 01910.Na has been reported to be selectively cytotoxic for the myeloid tumor cells without affecting normal hematopoiesis (44) . While induction of oxidative stress has not been described as a therapeutic principle in MDS, ROS plays an important role in the pathogenesis and is increased in MDS cells compared to normal bone marrow cells (reviewed in (45)). Given our findings, it thus appears plausible that generation of ROS contributes to the selective anti-tumor activity of ON
01910.Na in MDS.
Consistent with a report that ON 01910.Na inhibits PI3K signaling we detected a transcriptional response in drug treated CLL cells indicative of substantial PI3K inhibition. To do this, we selected two representative patients for gene expression analysis and exposed PBMCs to ON 01910.Na in a dose and time dependent fashion. In this way we generated 4 replicates of drug treated cells in each patient that also incorporate dose and time effects. Gene expression in treated cells was compared to untreated cells obtained at the same time points. We then tested whether ON 01910.Na induces the gene expression fingerprint of a PI3K inhibitor using GSEA to estimate the connection of ON 01910.Na induced gene expression changes with previously established signatures of the pan-PI3K inhibitor LY 294002. This approach termed "connectivity mapping" has been developed and used successfully to identify compounds affecting the same cellular pathways (46) . Indeed, the connection between the gene signatures of LY 0294002 and ON 01910.Na was highly significant (FDR 0.01 for downregulated genes; FDR 0.17 for upregulated genes; Supplementary Table S1, Fig. 2A ). Further supporting "on target" effects are the upregulation of genes controlled by FOXO. Transcription factors of the FOXO family are retained in the cytoplasm by PI3K and/or ERK dependent phosphorylation.
Upon downregulation of PI3K activity, unphosphorylated FOXO translocates to the nucleus and upregulates numerous genes involved in cell cycle arrest, apoptosis, and stress response (47) .
Finally, we also observed downregulation of a subset of genes that we have previously identified as target genes of BCR signaling in CLL cells (7) . Possible reasons why we observed only a partial downregulation of the BCR signature include PI3K independent regulation of some BCR target genes and incomplete inhibition of the pathway by ON 01910.Na, which has been reported to primarily inhibit PI3Kα and PI3Kβ (23), while BCR signaling activates PI3Kδ (11) . As reported by Prasad and colleagues, we did observe a decrease in pAKT in most samples (Fig.   2C ), while effects on p-mTOR, pS6K, and p4EBP1 were apparent in some but not other CLL samples tested (data not shown). These differences may be due to the former study testing only two cell lines, or could reflect differences between cell lines and primary samples.
The tumor microenvironment is increasingly recognized as a significant factor contributing to treatment resistance in CLL (8) . Strategies to target cells in the protective environment are therefore a priority. ON 01910.Na combines two complementary activities that could endow it with significant clinical activity. ROS activation can induce apoptosis, particularly in cells with high baseline ROS levels. CLL cells are reported to have high baseline ROS levels (42) and some of the key signals activated in the secondary lymphoid structures including BCR and CD40 signaling further increase ROS (48, 49) . In addition to increasing oxidative stress through inactivation of NRF2, PI3K inhibition may combine with ROS to target MCL-1, an important survival factor upregulated by stroma contact. MCL-1 protein stability is increased through phosphorylation by AKT (14) and glutathionylation (42) . Thus, ROS may destabilize MCL-1 through depletion of glutathione while PI3K inhibition blocks the effect of stroma (Fig.   5C , and (50)). While, treatment with a pan-PI3K inhibitor is sufficient to reverse the increase in CLL viability observed in co-culture with stroma cells (50) , or conferred by CD44 activation (17) , it alone does not induce significant apoptosis. In contrast, ON 01910.Na not only blocked the pro-survival effect of HK cells but induced apoptosis in >50% of cells even in the presence of stroma (Fig. 5B) . ON 01901.Na is also more cytotoxic in vitro than more specific inhibitors such 
